Pain Medicine, Interventional Pain Medicine · Shenandoah, TX
NPI
1396181350
Since 2013
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
111 Vision Park Blvd Ste 100
Shenandoah, TX, 77384
Phone (713) 714-1399
Groups this clinician bills Medicare through
Medicare paid, 2024
$587K
10,240 services
Medicare patients, 2024
188
Average age 72
Drug cost, 2024
$386K
8,632 prescriptions
Company payments, 2025
$3,445
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas S White was code J0665 (injection, bupivicaine, not otherwise specified, 0.5 mg), 2,086 times for 30 patients. In total Thomas S White billed 10,240 services in 85 codes, and Medicare paid $587K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg | Office | 2,086 | 30 | $0.01 | $18.13 |
| 99214 Office E&M - Established | Office | 1,380 | 168 | $86.11 | $119K |
| 80305 Drug Tests | Office | 1,207 | 162 | $12.18 | $15K |
| G3002 Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | Office | 1,188 | 167 | $56.10 | $67K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 827 | 138 | $192.01 | $159K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 752 | 63 | $0.71 | $537 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 677 | 141 | $11.89 | $8,053 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 220 | 22 | $0.08 | $18 |
| 99489 Chronic, Principal, and Transitional Care Management | Office | 197 | 49 | $51.97 | $10K |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 184 | 65 | $96.18 | $18K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 144 | 50 | $45.26 | $6,517 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 81 | 43 | $34.55 | $2,799 |
| Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | Office | 75 | 18 | $0.28 | $21.24 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 70 | 18 | $0.49 | $34.01 |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 68 | 68 | $110.67 | $7,526 |
By year: 2022 $358K for 5,310 services; 2023 $626K for 8,614 services; 2024 $587K for 10,240 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80305 Drug Tests | 1,207 | 162 | $12.18 | $15K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 827 | 138 | $192.01 | $159K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 68 | 68 | $110.67 | $7,526 |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 58 | 28 | $153.46 | $8,901 |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 36 | 35 | $241.98 | $8,711 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas S White prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 1,815 prescriptions and refills. In total Thomas S White wrote 8,632 Medicare prescriptions that cost $386K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,815 | 1,815 | 299 | $57K |
| Pregabalin Generic | 1,056 | 1,110 | 198 | $18K |
| Cyclobenzaprine Hcl Generic | 697 | 751 | 134 | $5,831 |
| Tizanidine Hcl Generic | 554 | 610 | 96 | $6,634 |
| Gabapentin Generic | 499 | 605 | 80 | $6,472 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 467 | 467 | 87 | $16K |
| Meloxicam Generic | 418 | 435 | 85 | $1,423 |
| Oxycodone Hcl Generic | 303 | 303 | 51 | $4,574 |
| Trazodone Hcl Generic | 294 | 386 | 49 | $2,823 |
| Methocarbamol Generic | 250 | 278 | 49 | $4,548 |
| Tramadol Hcl Generic | 182 | 182 | 47 | $1,880 |
| Lidocaine Generic | 173 | 188 | 40 | $14K |
| Diclofenac Sodium Generic | 164 | 172 | 36 | $5,254 |
| Hydromorphone Hcl Generic | 134 | 134 | 29 | $1,984 |
| Buprenorphine Generic | 107 | 107 | 31 | $29K |
Brand drugs: 284 claims; generic drugs: 8,348 claims; opioid claims: 3,242.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas S White $3,445 ($3,445 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbott Laboratories with $1,421.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 24 | $1,421 |
| Globus Medical, Inc. GMED | 7 | $1,321 |
| Medtronic, Inc. MDT | 5 | $328 |
| Indivior Inc. INDV | 4 | $93.05 |
| Nalu Medical, Inc. | 3 | $52.55 |
| Axsome Therapeutics, Inc. AXSM | 2 | $50.52 |
| MML US, Inc. | 1 | $47.5 |
| Azurity Pharmaceuticals, Inc. | 2 | $42.53 |
| Intrinsic Therapeutics | 1 | $28.57 |
| Stryker Corporation SYK | 1 | $23.17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.